Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine in Adults in Portugal Versus "No Vaccination" and Versus Vaccination with the 23-Valent Pneumococcal Polysaccharide Vaccine

The burden of pneumococcal disease in adults is substantial from a social and economic point of view. This study assessed the cost-effectiveness of the 13-valent pneumococcal conjugate vaccine (PCV13) for the prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults versus &qu...

ver descrição completa

Detalhes bibliográficos
Autor principal: Gouveia, M (author)
Outros Autores: Jesus, G (author), Inês, M (author), Costa, J (author), Borges, M (author)
Formato: article
Idioma:eng
Publicado em: 2021
Assuntos:
Adolescent
Adult
Aged
Aged, 80 and over
Humans
Middle Aged
Pneumococcal Infections
Pneumococcal Vaccines
Portugal
Quality-Adjusted Life Years
Vaccination
Vaccines, Conjugate
Young Adult
Cost-Benefit Analysis
CHLC FAR
Texto completo:http://hdl.handle.net/10400.17/3666
País:Portugal
Oai:oai:repositorio.chlc.min-saude.pt:10400.17/3666

Texto Completo

http://hdl.handle.net/10400.17/3666

Registos relacionados